<DOC>
	<DOCNO>NCT00217568</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel together carboplatin work treat patient relapse stage III stage IV ovarian epithelial primary peritoneal cavity cancer .</brief_summary>
	<brief_title>Docetaxel Carboplatin Treating Patients With Relapsed Stage III Stage IV Ovarian Epithelial Primary Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity docetaxel carboplatin patient platinum-sensitive stage III IV ovarian epithelial primary peritoneal cavity cancer first relapse . - Determine response rate ( complete partial response ) patient treat regimen . - Determine relapse rate event-free survival overall survival rate patient treated regimen . OUTLINE : This multicenter study . Patients receive docetaxel IV 1 hour carboplatin IV 30 minute day 1 . Patients also receive pegfilgrastim subcutaneously day 2 . Treatment repeat every 21 day 6 course . After completion study treatment , patient follow 3 week , every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study within 4-5 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial primary peritoneal cavity cancer Stage III IV disease No borderline tumor Measurable evaluable disease Measurable disease , define evidence disease physical examination radiographic evaluation Evaluable disease , define CA 125 ≥ 100 U/mL ( confirm 2 blood test perform ≥ 1 week apart ) In first relapse Platinumsensitive disease , define initial relapse &gt; 6 month completion platinumbased regimen PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin normal Meets 1 follow criterion : SGOT and/or SGPT ≤ 1.5 time upper limit normal ( ULN ) AND alkaline phosphatase ( AP ) ≤ 2.5 time ULN SGOT and/or SGPT ≤ 5.0 time ULN AND AP normal Renal Creatinine ≤ 2.0 mg/dL Creatinine clearance &gt; 50 mL/min Cardiovascular LVEF ≥ 50 % No poorly control arrhythmia No unstable coronary artery disease myocardial infarction within past year Other HIV negative No preexist peripheral neuropathy &gt; grade 2 No history allergy study drug PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy recover Endocrine therapy Not specify Radiotherapy At least 3 week since prior radiotherapy recover Surgery Recovered recent prior surgery Other No concurrent myelosuppressive therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>